Zenith DrugsShare price, financial results, shareholding and management

NSE Emerge · ZENITHDRUGPharmaceuticals & BiotechnologyListed 27 Feb 2024IPO ₹79
zenithdrugs.com ↗Live price on NSE ↗ISIN INE0QWN01013 · Lot 800 shares · ₹33,600
₹42.00
0.00% on the day
Close · 17 Nov 2026
Valuation
Market cap
₹72 cr
Stock P/E
18.3peers 19.1
Book value
₹42.8
Price to book
0.98
EV / operating profit
10.4
Market cap to sales
0.42
Returns and growth
ROCE · FY26
8.9%
ROE · FY26
5.5%
ROE, 3-year average
13.9%
Operating margin · FY26
7.1%peers 10.2%
Sales growth, 3 years
14.5%
Profit growth, 3 years
-7.6%
Safety
Debt to equity
0.75peers 0.34
Borrowings
₹55.1 cr
Interest cover
2.0×
Cash from business / op. profit
73%
Debtor days
156
Pledged
0.00%
Ownership and share
Promoter holding
69.98%
Change in promoter holding
0.00 pts
Shareholders
1,435
52-week high / low
₹60 / ₹33
Dividend yield
0.00%
Face value
₹10

Tap or hover on any figure for what it means. Our arithmetic on reported figures, at the latest close.

newboard is reading this company's filings. Its plain description, key points, management and study will appear here soon; the figures below are worked out from what it has filed.

Zenith Drugs share price chart

₹42.00-22.29% 1 year

Close on 17 Nov 2026 · 0.00% on the day · Vol 16,800

Daily prices to 17 Nov 2026, adjusted for splits and bonuses. Closing prices only: check the exchange for the live price.

Share price returns

To the close of 17 Nov 2026

1 month
+3.4%
3 months
-6.7%
6 months
+7.7%
1 year
-22.3%
Since IPO
-46.8%
Traded a day, 20 days
₹0.02 cr
Taken for delivery
88%

Business growth

Sales and net profit, from the reported results

SalesProfit
FY26 on FY25+28%-45%
3 years, a year+15%-8%
Latest half, H2 FY26+42%+12%

Zenith Drugs revenue and profit growth

Half-yearly results · Profit and loss

Sales have grown steadily. Last year profit fell even as sales rose, so the company kept less from each rupee of sales.

Sales and net profit, every year, ₹ crore
SalesNet profit
050100150200Sales, FY20: 78 ₹ cr78Net profit, FY20: 3 ₹ cr3FY20Sales, FY21: 72 ₹ cr72Net profit, FY21: 3 ₹ cr3FY21Sales, FY22: 92 ₹ cr92Net profit, FY22: 3 ₹ cr3FY22Sales, FY23: 114 ₹ cr114Net profit, FY23: 5 ₹ cr5FY23Sales, FY24: 131 ₹ cr131Net profit, FY24: 10 ₹ cr10FY24Sales, FY25: 133 ₹ cr133Net profit, FY25: 7.2 ₹ cr7.2FY25Sales, FY26: 171 ₹ cr171Net profit, FY26: 3.9 ₹ cr3.9FY26
The latest halves, ₹ crore
SalesNet profit
0255075100Sales, H1FY24: 69 ₹ cr69Net profit, H1FY24: 6 ₹ cr6H1FY24Sales, H2FY24: 62 ₹ cr62Net profit, H2FY24: 4 ₹ cr4H2FY24Sales, H1FY25: 68 ₹ cr68Net profit, H1FY25: 6 ₹ cr6H1FY25Sales, H2FY25: 65.6 ₹ cr65.6Net profit, H2FY25: 1.4 ₹ cr1.4H2FY25Sales, H1FY26: 78.2 ₹ cr78.2Net profit, H1FY26: 2.3 ₹ cr2.3H1FY26Sales, H2FY26: 93 ₹ cr93Net profit, H2FY26: 1.6 ₹ cr1.6H2FY26

SME companies report every six months. In the latest half, sales were higher than in the same half a year before. Profit grew more slowly than sales, so each rupee of sales left a little less profit.

Zenith Drugs half-yearly results

SME companies report every six months · ₹ crore

₹ crore · growth on the same half a year before
H1FY24H2FY24H1FY25H2FY25H1FY26H2FY26
Sales69626865.6378.2293
Expenses58566158.8372.0587.01
Operating profit11676.806.175.99
OPM16.0%9.0%10.0%10.4%7.9%6.4%
Interest1212.472.533.08
Depreciation1112.2833.05
Profit before tax8663.542.343.05
Net profit6461.442.341.61

Zenith Drugs profit and loss

Full years to March, FY20 to FY26 · ₹ crore, consolidated where reported

₹ crore
FY20FY21FY22FY23FY24FY25FY26
Sales787292114131133.32171.22
Expenses716485104114119.74159.06
Operating profit77791713.5812.16
OPM9.0%10.0%8.0%8.0%13.0%10.2%7.1%
Other income001112.615.10
Interest112233.715.61
Depreciation111112.976.05
Exceptional and other items··-1·-1··
Profit before tax5547139.265.39
Tax rate40.0%40.0%25.0%28.6%23.1%22.7%26.9%
Net profit3335107.163.94
EPS ₹····5.594.182.30
Dividend payout0.0%0.0%0.0%0.0%9.0%0.0%0.0%

The years to FY24 come rounded to the nearest crore in the source.

Exceptional and other items: profit before tax beyond operating profit, other income, interest and depreciation, such as one-off items or a share of associates' profit, as reported.

Zenith Drugs profitability

Margins and returns on capital

Last year the company kept less from each rupee of sales than the year before. It earns a low return on the money it uses.

Operating margin, every year

Per cent of sales kept before interest, depreciation and tax

0%5%10%15%FY20: 9.0%9.0%FY20FY21: 10.0%10.0%FY21FY22: 8.0%8.0%FY22FY23: 8.0%8.0%FY23FY24: 13.0%13.0%FY24FY25: 10.2%10.2%FY25FY26: 7.1%7.1%FY26
Per cent
FY20FY21FY22FY23FY24FY25FY26
Operating margin9.0%10.0%8.0%8.0%13.0%10.2%7.1%
Tax rate40.0%40.0%25.0%28.6%23.1%22.7%26.9%
ROCE·28.0%21.5%24.1%24.5%12.7%8.9%
ROE·38.0%27.5%33.6%25.2%10.9%5.5%
Dividend payout0.0%0.0%0.0%0.0%9.0%0.0%0.0%

Zenith Drugs debt and cash flow

Balance sheet · Cash flow · Working capital

The company's own money, its net worth, has grown. Its loans are smaller than its own money. Last year the business brought in more cash than it showed as profit. It spent more on assets and investments than the business brought in, and raised the rest from loans or shares. Customers take about as long to pay as they did in FY24.

Its own money and its borrowings, ₹ crore
Net worthBorrowings
020406080Net worth, FY20: 6.4 ₹ cr6.4Borrowings, FY20: 12 ₹ cr12FY20Net worth, FY21: 9.4 ₹ cr9.4Borrowings, FY21: 15 ₹ cr15FY21Net worth, FY22: 12.4 ₹ cr12.4Borrowings, FY22: 19 ₹ cr19FY22Net worth, FY23: 17.4 ₹ cr17.4Borrowings, FY23: 26 ₹ cr26FY23Net worth, FY24: 62 ₹ cr62Borrowings, FY24: 25 ₹ cr25FY24Net worth, FY25: 69.4 ₹ cr69.4Borrowings, FY25: 48.6 ₹ cr48.6FY25Net worth, FY26: 73.3 ₹ cr73.3Borrowings, FY26: 55.1 ₹ cr55.1FY26
Cash from the business against net profit, ₹ crore
Cash from the businessNet profit
-20-10010Cash from the business, FY20: 3 ₹ cr3Net profit, FY20: 3 ₹ cr3FY20Cash from the business, FY21: -1 ₹ cr-1Net profit, FY21: 3 ₹ cr3FY21Cash from the business, FY22: 5 ₹ cr5Net profit, FY22: 3 ₹ cr3FY22Cash from the business, FY23: -5 ₹ cr-5Net profit, FY23: 5 ₹ cr5FY23Cash from the business, FY24: -13 ₹ cr-13Net profit, FY24: 10 ₹ cr10FY24Cash from the business, FY25: -5.5 ₹ cr-5.5Net profit, FY25: 7.2 ₹ cr7.2FY25Cash from the business, FY26: 8.9 ₹ cr8.9Net profit, FY26: 3.9 ₹ cr3.9FY26

Bars below the line are cash going out.

Zenith Drugs balance sheet

At each 31 March · ₹ crore

₹ crore
FY20FY21FY22FY23FY24FY25FY26
Equity capital0.400.400.400.401717.1517.15
Reserves6912174552.2356.17
Net worth6.409.4012.4017.406269.3873.32
Borrowings121519262548.5755.11
Other liabilities25.6022.6037.6054.604843.5359.09
Total liabilities44476998135161.48187.52
Fixed assets6910121140.2637.24
Capital work in progress30304314
Investments0000000
Other assets35385686120118.22136.28
Receivables·····60.5873.35
Inventory·····39.6142.42
Cash·····0.260.26
Trade payables·····40.1855.59

Zenith Drugs cash flow

₹ crore

₹ crore
FY20FY21FY22FY23FY24FY25FY26
Cash from operations3-15-5-13-5.478.88
Cash from investing-5-2-5026-31.41-13.72
Cash from financing1315-428.394.83
Net cash flow-10109-8.49-0.01
Capital spending·····013.75

Working capital

Days

Days
FY20FY21FY22FY23FY24FY25FY26
Debtor days119119128159188166156
Inventory days295296192249277257
Days payable155155274413412281337
Cash conversion cycle-717-50-622516377
Working capital days142416391129174

Zenith Drugs peers and competitors

Listed SME companies in the same industry

By sales, Zenith Drugs is number 5 of the 34 listed SME companies in pharmaceuticals & biotechnology.

Each company's latest full year and its latest close; companies the exchange puts in the same industry, whose businesses can differ a good deal. A list, not a comparison of their shares.

CompanyMarket cap ₹ crP/ESales ₹ crProfit ₹ crOp. marginDebt/equity
Sat Kartar Life22012.92011712.0%0.03
Infinium Pharmachem47138.719012.211.4%0.19
Zenith Drugs7218.31713.97.1%0.75
Mono Pharmacare1644.61660.42.4%1.79
Astonea Labs34168.114859.0%0.74
Influx Healthtech63230.814720.520.3%0.00
Jfl Life Sciences355.51316.48.9%0.47
Dipna Pharmachem113.512933.9%0.21
Trident Lifeline48125.31291922.0%0.73
Chandra Bhagat Pharma3210.511633.3%0.50
Quest Laboratories15410.31121516.3%0.08
Median of the 10 others18719.11399.310.2%0.34

Zenith Drugs shareholding pattern

Promoters, FIIs, DIIs, HNIs and small holders

The promoters own more than half the company. Big foreign and Indian funds own very little. The number of shareholders is about the same.

Promoters
69.98%
0.00 pts since Feb 24
Foreign investors (FIIs)
0.06%
at Mar 25; not in the latest pattern
Indian institutions (DIIs)
0.00%
at Mar 25; not in the latest pattern
HNIs (over ₹2 lakh each)
7.44%
+7.44 pts since Feb 24
Small holders (up to ₹2 lakh)
17.29%
+6.08 pts since Feb 24
Companies and others
5.29%
-2.44 pts since Feb 24
Number of shareholders
1,435
1,333 in Feb 24

Zenith Drugs shareholding pattern

Per cent of shares, from the patterns filed with the exchange. Tap + to see everyone holding 1% or more in that group. HNIs and small holders show only where the pattern was filed in full.

Feb 24Mar 24Sep 24Mar 25Sep 25Mar 26
Promoters69.98%69.98%69.98%69.98%69.98%69.98%
Foreign investors (FIIs)7.40%5.81%0.42%0.06%--
Indian institutions (DIIs)3.68%1.93%0.00%0.00%--
HNIs (over ₹2 lakh each)0.00%2.01%8.09%7.30%8.01%7.44%
Small holders (up to ₹2 lakh)11.21%13.19%17.48%18.26%17.25%17.29%
Companies and others7.73%7.08%4.03%4.40%4.76%5.29%
Number of shareholders1,3331,1171,3551,5441,4661,435

The named holders are at 31 March 2026, beside 30 Sept 2025, each under the group the pattern files them in.

Zenith Drugs latest news and announcements

Announcements · Documents · Corporate actions

What changed recently

Each half-year is set against the same half a year earlier

  • H2 FY26: sales ₹93 cr (+42%), net profit ₹1.6 cr (+12%) on H2 FY25.
  • Shareholding, 31 March 2026: promoters unchanged at 69.98%.

Zenith Drugs annual reports, earnings calls and documents

Every document links to its source; “read” marks those this page is built from

Zenith Drugs share split, bonus and dividends

From the corporate actions the company announces on the exchange

  • DividendDIVIDEND - RE 0.5 PER SHAREex-date 17 Sept 2024
Checks we ran on Zenith Drugs' data · 9

Before any number shows, it goes through the same checks. A figure that fails is held back, never shown as if it were right.

  • ✓Balance sheet totals add up for FY25 and FY26.
  • ✓Market cap uses the share count in the latest shareholding pattern (1,71,48,800 shares).
  • ✓The share capital in the FY26 results matches the share count in the shareholding pattern.
  • ✓Promoter pledge figures are within possible limits in every shareholding pattern shown.
  • ✓Promoter and public holdings add up to 100% in every shareholding pattern shown.
  • ✓The two half-years of FY26 add up to the full-year sales.
  • ✓Earnings per share moves in line with profit across the years shown.
  • ✓Revenue and profit are reported for every year shown, FY20 to FY26.
  • iPrices run to the close on 14 Oct 2026, from the exchange's daily figures.

Questions people ask about Zenith Drugs

What does Zenith Drugs do?

Zenith Drugs is an SME company listed on NSE Emerge, in pharmaceuticals & biotechnology.

What is the share price of Zenith Drugs?

₹42 at the close on 17 Nov 2026, from the exchange's daily figures.

What is the market cap of Zenith Drugs?

₹72 cr at the close on 17 Nov 2026, on 1,71,48,800 shares.

What is the P/E of Zenith Drugs?

18.3 times FY26 profit at the close on 17 Nov 2026 (our arithmetic).

What are Zenith Drugs' revenue and profit?

Revenue ₹171 cr and profit after tax ₹4 cr in FY26.

Who are the promoters of Zenith Drugs?

The promoter group; promoters held 69.98% at 31 March 2026.

What was the IPO price of Zenith Drugs?

₹79 a share; it listed on 27 Feb 2024.

What is Zenith Drugs' website?

www.zenithdrugs.com

More SME companies like Zenith Drugs

Other listed SME companies in pharmaceuticals & biotechnology, the closest in size first, each read from its own documents.

Every listed SME company in Pharmaceuticals & Biotechnology → · SME companies listed in 2024 →

Built from 28 exchange announcements, 6 shareholding patterns and 7 years of reported results. Every figure carries its source; where the documents are silent, the page says so.